Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?
Published: 09 October 2020
-
Views:
61
-
Likes:
7
-
Views:
61
-
Likes:
7
-
9m 33sPart 1 SGLT2s as a Heart Failure Drug – How Did We Get Here? Martin R Cowie, Anne Cornelissen
-
10m 1sPart 2 Emerging Data SGLT2 Inhibitors in Heart Failure Faiez Zannad
-
11m 45sPart 3 Guidelines and Practice Implications Sanjay Kaul
-
16m 28sPart 4 Q&A Discussion Martin R Cowie, Faiez Zannad, Sanjay Kaul
Overview
This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.
The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.
Learning Objectives
- Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
- Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
- Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors
More from this programme
Part 1
SGLT2s as a Heart Failure Drug – How Did We Get Here?
Part 2
Emerging Data SGLT2 Inhibitors in Heart Failure
Part 3
Guidelines and Practice Implications
Part 4
Q&A Discussion
| 1 session | |
| Q&A Discussion | Watch now |
Part 5
Follow-up Peer-to Peer Discussion
| 1 session | |
| Follow-up Peer-to Peer Discussion | Watch now |
Faculty Biographies
Andrew JS Coats
Director of the Monash Warwick Alliance and Academic Vice-President
Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.
Prof Coats attended Melbourne Grammar School and studied at Oxford and Cambridge. He has a higher doctorates from Oxford (DM) and Imperial (DSc.).
Prof Coats was appointed Viscount Royston Professor of Cardiology at Imperial College in 1996 and Director of Cardiology and Associate Medical Director of the Royal Brompton and Harefield NHS trust. Professor Coats was appointed Dean of Medicine at the University of Sydney in 2002, and subsequently Deputy Vice-Chancellor. Professor Coats was most recently CEO of the Norwich Research Park, the UK's oldest and largest research and innovation park.
Prof Coats research interests are chronic heart failure, hypertension, and organizational…
Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC
Dr Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).
Dr Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension.
Dr Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.